C12N2760/14133

LIPID-PEPTIDE FUSION INHIBITORS AS SARS-COV-2 ANTIVIRALS

Described herein is a composition and method of treating COVID-19 with lipid-peptide fusion antiviral therapy. Also described is a composition and method of treating Ebola with lipid-peptide fusion antiviral therapy.

EBOLAVIRUS PRE-HAIRPIN INTERMEDIATE MIMICS AND METHODS OF USE

Ebolavirus is a highly lethal filovirus that causes hemorrhagic fever in humans and non-human primates. With no approved treatments or preventatives, the development of an anti-ebolavirus therapy to protect against natural infections and potential weaponization is an urgent unmet global health need. The design, biophysical characterization, and validation of peptide mimics of the ebolavirus N-trimer (“N-trimer mimics”) are described herein.

ANTIVIRAL STRUCTURALLY-STABILIZED EBOLAVIRUS PEPTIDES AND USES THEREOF

This disclosure features structurally-stabilized Ebola virus antiviral peptides. Also disclosed are methods of using such structurally-stabilized peptides in the treatment or prevention of an Ebola virus infection or Ebola virus disease.

SELF-AMPLIFYING MESSENGER RNA

Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes an interferon effector.

EBOLAVIRUS SURFACE GLYCOPROTEIN PEPTIDES, CONJUGATES, AND USES THEREOF
20250288658 · 2025-09-18 ·

This disclosure relates to structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) Ebolavirus peptides and variants thereof, and structurally-stabilized (e.g., stapled, e.g., hydrocarbon stapled) Ebolavirus peptides and variants thereof, conjugated with polyethylene glycol (PEG) and/or cholesterol (or a variant thereof, e.g., thiocholesterol), e.g., a generated PEG(n)-cholesterol or PEG(n)-thiocholesterol derivatization to further optimize activity, and methods for using such structurally-stabilized peptide conjugates in the prevention and treatment of an Ebolavirus infection or disease in a subject (e.g., human, non-human primate, or fruit bat). The disclosure also relates to methods of using such structurally-stabilized peptides and conjugates in the prevention and treatment of a Marburg virus infection, a Bombali ebolavirus infection, or a Mengla dianlovirus infection in a subject.